Emotion-induced brain activation across the menstrual cycle in individuals with premenstrual dysphoric disorder and associations to serum levels of progesterone-derived neurosteroids

[1]  M. Bixo,et al.  Differential grey matter structure in women with premenstrual dysphoric disorder: evidence from brain morphometry and data-driven classification , 2022, Translational Psychiatry.

[2]  A. Hirschberg,et al.  A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder , 2021, Psychoneuroendocrinology.

[3]  C. Epperson,et al.  Ulipristal Acetate for Treatment of Premenstrual Dysphoric Disorder: A Proof-of-Concept Randomized Controlled Trial. , 2020, The American journal of psychiatry.

[4]  Belinda Pletzer,et al.  Neuroimaging the menstrual cycle_ A multimodal systematic review , 2020 .

[5]  E. Luders,et al.  Progesterone – Friend or foe? , 2020, Frontiers in Neuroendocrinology.

[6]  R. Lanzenberger,et al.  Neuroimaging premenstrual dysphoric disorder: A systematic and critical review , 2020, Frontiers in Neuroendocrinology.

[7]  Ninon Burgos,et al.  New advances in the Clinica software platform for clinical neuroimaging studies , 2019 .

[8]  C. Weise,et al.  Clusters of premenstrual symptoms in women with PMDD: Appearance, stability and association with impairment. , 2018, Journal of psychosomatic research.

[9]  M. Bixo,et al.  Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder , 2018, Journal of neuroendocrinology.

[10]  A. Hirschberg,et al.  Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial , 2017, Psychoneuroendocrinology.

[11]  L. Pessoa.  A Network Model of the Emotional Brain , 2017, Trends in Cognitive Sciences.

[12]  F. D’Agata,et al.  Consensus Paper: Cerebellum and Emotion , 2016, The Cerebellum.

[13]  M. Doverskog,et al.  GABAA receptor modulating steroid antagonists (GAMSA) are functional in vivo , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  H. Stenlund,et al.  Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls—a pilot study , 2016, Psychopharmacology.

[15]  D. Rubinow,et al.  5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder , 2016, Neuropsychopharmacology.

[16]  U. Ehlert,et al.  How to use and interpret hormone ratios , 2016, Psychoneuroendocrinology.

[17]  E. Comasco,et al.  Neuroimaging the Menstrual Cycle and Premenstrual Dysphoric Disorder , 2015, Current Psychiatry Reports.

[18]  M. Bixo,et al.  Isoallopregnanolone antagonize allopregnanolone-induced effects on saccadic eye velocity and self-reported sedation in humans , 2015, Psychoneuroendocrinology.

[19]  F. Kapczinski,et al.  Progesterone and its metabolites as therapeutic targets in psychiatric disorders , 2014, Expert opinion on therapeutic targets.

[20]  Stephen M. Smith,et al.  Permutation inference for the general linear model , 2014, NeuroImage.

[21]  M. Fredrikson,et al.  Social stimulation and corticolimbic reactivity in premenstrual dysphoric disorder: a preliminary study , 2014, Biology of Mood & Anxiety Disorders.

[22]  Rupert Lanzenberger,et al.  Emotional fronto‐cingulate cortex activation and brain derived neurotrophic factor polymorphism in premenstrual dysphoric disorder , 2014, Human brain mapping.

[23]  M. Fredrikson,et al.  Premenstrual dysphoric disorder and prefrontal reactivity during anticipation of emotional stimuli , 2013, European Neuropsychopharmacology.

[24]  K. Berman,et al.  Abnormalities of dorsolateral prefrontal function in women with premenstrual dysphoric disorder: a multimodal neuroimaging study. , 2013, The American journal of psychiatry.

[25]  H. Garavan,et al.  The effect of premenstrual dysphoric disorder and menstrual cycle phase on brain activity during response inhibition. , 2012, Journal of affective disorders.

[26]  M. Gingnell,et al.  Menstrual cycle effects on amygdala reactivity to emotional stimulation in premenstrual dysphoric disorder , 2012, Hormones and Behavior.

[27]  C. Epperson,et al.  Premenstrual dysphoric disorder: evidence for a new category for DSM-5. , 2012, The American journal of psychiatry.

[28]  Marisa O. Hollinshead,et al.  The organization of the human cerebral cortex estimated by intrinsic functional connectivity. , 2011, Journal of neurophysiology.

[29]  M. Mandelkern,et al.  Neuroimaging Evidence of Cerebellar Involvement in Premenstrual Dysphoric Disorder , 2011, Biological Psychiatry.

[30]  M. Bixo,et al.  Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. , 2009, American journal of obstetrics and gynecology.

[31]  Stephen M. Smith,et al.  Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference , 2009, NeuroImage.

[32]  A. Margioris,et al.  Neurosteroids as modulators of neurogenesis and neuronal survival , 2008, Trends in Endocrinology & Metabolism.

[33]  Giuseppe Iaria,et al.  Disconnection in prosopagnosia and face processing , 2008, Cortex.

[34]  Luke J. Chang,et al.  Toward a functional neuroanatomy of premenstrual dysphoric disorder. , 2008, Journal of affective disorders.

[35]  K. Petersson,et al.  Progesterone selectively increases amygdala reactivity in women , 2008, Molecular Psychiatry.

[36]  J. Buitelaar,et al.  Effects of allopregnanolone on sedation in men, and in women on oral contraceptives , 2007, Psychoneuroendocrinology.

[37]  B. Chronwall,et al.  Role of microsomal retinol/sterol dehydrogenase-like short-chain dehydrogenases/reductases in the oxidation and epimerization of 3alpha-hydroxysteroids in human tissues. , 2007, Endocrinology.

[38]  T. Bäckström,et al.  Neurosteroid modulation of allopregnanolone and GABA effect on the GABA-A receptor , 2006, Neuroscience.

[39]  J. Neumaier,et al.  Estrogen Selectively Increases Tryptophan Hydroxylase-2 mRNA Expression in Distinct Subregions of Rat Midbrain Raphe Nucleus: Association between Gene Expression and Anxiety Behavior in the Open Field , 2006, Biological Psychiatry.

[40]  Mark H. Johnson.  Subcortical face processing , 2005, Nature Reviews Neuroscience.

[41]  T. Bäckström,et al.  Isoallopregnanolone; an antagonist to the anaesthetic effect of allopregnanolone in male rats. , 2005, European journal of pharmacology.

[42]  R. Dolan,et al.  Distant influences of amygdala lesion on visual cortical activation during emotional face processing , 2004, Nature Neuroscience.

[43]  Peter W. Jones,et al.  The effectiveness of GnRHa with and without ‘add‐back’ therapy in treating premenstrual syndrome: a meta analysis , 2004, BJOG : an international journal of obstetrics and gynaecology.

[44]  M. Buonocore,et al.  Posterior cingulate cortex activation by emotional words: fMRI evidence from a valence decision task , 2003, Human brain mapping.

[45]  Michael Brady,et al.  Improved Optimization for the Robust and Accurate Linear Registration and Motion Correction of Brain Images , 2002, NeuroImage.

[46]  Francesco Fera,et al.  The Amygdala Response to Emotional Stimuli: A Comparison of Faces and Scenes , 2002, NeuroImage.

[47]  H. Sveinsdóttir,et al.  Menstrual cycle symptom variation in a community sample of women using and not using oral contraceptives , 2000, Acta obstetricia et gynecologica Scandinavica.

[48]  S. Mellon,et al.  Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[49]  A. Guidotti,et al.  Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D. Rubinow,et al.  Premenstrual syndrome: evidence for symptom stability across cycles. , 1997, The American journal of psychiatry.

[51]  S. Paul,et al.  Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. , 1986, Science.

[52]  N. Woods,et al.  Concordance of perimenstrual symptoms across two cycles. , 1985, Research in nursing & health.

[53]  D. Sharp,et al.  The role of the posterior cingulate cortex in cognition and disease. , 2014, Brain : a journal of neurology.

[54]  J. Endicott,et al.  Daily Record of Severity of Problems (DRSP): reliability and validity , 2005, Archives of Women's Mental Health.